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Summary: The interaction between normal or glycated haemoglobin and the cytoplasmic surface of human
erythrocyte ghost membranes from normal and diabetic individuals was studied at low pH and low ionic
strength. Haemoglobin binding to the membrane was monitored by quenching of a fluorescent probe, 12-(9-
anthroyl) stearic acid, embedded in the membrane. The quenching occurs by energy transfer from the probe
to the membrane-bound haemoglobin molecules. It was found that both glycated and non-glycated haemo-
globin bind with higher affinity to membranes from diabetics than to control erythrocyte ghosts. The binding
of glycated haemoglobin is significantly less than that of normal haemoglobin to red blood cell membranes
from both normal and diabetic individuals.
Introduction
Non-enzymatic glycosylation alters the physical and
chemical properties of proteins. It has been reported
that glycation changes the conformation and function
of human serum albumin (1), inhibits the binding of
fibronectin to matrix components (2), leads to partial
unfolding of oc-crystallin (3), decreases binding of
sulphoxazole to serum albumin (4) and alters the
ability of haemoglobin to bind oxygen and glycerate
2,3-bisphosphate (5). The levels of glycation of most
proteins are elevated in diabetes mellitiis. This phe-
nomenon seems to be especially important for pro-
teins with slow turnover rates such as lens crystallins
(6), collagen (7), and the blood proteins: albumin (8),
haemoglobin (9) and erythrocyte membrane proteins
(10, 11).
Several studies have been reported on the binding of
haemoglobin to erythrocyte membranes. It has been
shown that haemoglobin binds to the cytoplasmic
surface of this membrane, specifically to the cyto-
plasmic domain of band 3 protein. This binding is
reversible, and mainly electrostatic in nature (12—18).
Oxy-, deoxy-, and sickle cell haemoglobins were found
to bind to the band 3 with different affinities (17, 19,
20). In view of the above findings it seemed of par-
ticular interest to study the association of normal and
glycated haemoglobins with erythrocyte membranes
from normal and diabetic individuals. This was
achieved by measurements of resonance energy trans-
fer between a fluorescent probe inserted into the mem-
brane and the haem of membrane-bound haemoglo-
bin under conditions of low pH, low ionic strength
and low concentrations of haemoglobin. The method
has been described in detail by Shaklai et al. (12).
Materials and Methods
Chemicals were of analytical grade obtained from POCH (Gli-
wice, Poland) and Sigma Ltd. (glucose, fluorescent label 12-(9-
anthroyl) stearie acid, human haemoglobin). Haemoglobin was
used without further purification and considered as non-gly-
cated Hb.
Glycation of haemoglobin
Human haemoglobin (5 g/1) was incubated in a 1.67 moi/1
solution of glucose in 10 mmol/1 sodium phosphate buffer, pH
8.0 with 0.2 g/1 sodium azide at 37 °C for 98 hours. At the same
time a control sample was run in which haemoglobin was
incubated under the same conditions, but without glucose in
the incubation medium. At the end of the incubation, the
haemoglobin solutions (1.85 g/1 Hb) were dialysed against dis-
tilled water, and then against 5 mmol/1 phosphate buffer, pH
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6.0. These solutions were used for fluorescence quenching meas^
urements. Haemoglobin was determined by the method of
Drabkin (21). As the rate of formation of the Amadori product
for haemoglobin is about 4—5 times lower compared to human
serum albumin, the incubation of haemoglobin with glucose
should result in a glycated haemoglobin formation of 0.05%
per day and mraol glucose (22, 23). Haemoglobin obtained
under these experimental conditions is here-after called "gly-
cated haemoglobin".
Preparat ion of labelled ghosts
Blood samples from 8 type I diabetic patients were obtained
from the Diabetological Clinic of the Medical Academy of
Lodz. Samples from 8 healthy control patients were from the
Central Blood Bank of Lodz. Red blood cell ghosts, free of
haemoglobin, were obtained exactly as previously described
(12). Briefly, erythrocytes were washed 4 times with phosphate-
bufTered saline (0.15 mol/1 NaCl in 5 mmol/1 potassium phos-
phate, pH 8.0). Haemolysis was performed at a 1:40 volume
ratio of packed erythrocytes to 5 mmol/1 phosphate buffer at
pH 8.O. Next, ghosts were washed 5 — 6 times with this buffer
until the supernatant was free of haemoglobin. The optical
absorbances of ghost suspensions were measured at 415 nm.
Ghosts which contained less than 0.5% of the haemoglobin
which was added during fluorescence measurements were con*
sidered to be free of haemoglobin. The unsealed ghosts were
equilibrated with 50 mmol/1 NaCl at pH 8.0 to release mem-
brane-bound aldolase and glyceraldehyde-3-phosphate dehy-
drogenase (24), and the salt was then replaced by 5 mmol/1
phosphate buffer, pH 8.0 by dialysis. Ghosts were labelled with
the negatively charged fluorophore 12-(9-anthroyl) stearic acid
in a 1:200 probe to membrane lipids weight ratio. After 1 hour
incubation, the labelled membranes were washed with 5 mmol/1
phosphate buffer, pH 8.O. Finally, ghosts were suspended in
5 mmol/1 phosphate buffer at pH 6.0 at a ghost concentration
of 6 χ 106/1. For each sample, fluorescence quenching by nor-
mal and glycated haemoglobin was determined.
Fluorescence measurements
All fluorescence measurements were performed at 25 °C with a
JY-3 spectrofluorimeter Jobin-Yvon, Longjumeau, France. Flu-
orescence quenching was achieved by the addition of small
aliquots (1 μΐ) of Hb or glycated Hb solution to the 3 ml of
ghost suspensions. As a result of haemoglobin binding to the
membrane, the acceptor (haem) and the donor (12-(9-anthroyl)
stearic acid) groups are brought sufficiently close for energy
transfer to occur, resulting in a reduced fluorescence emission
from 12-(9-anthroyl) stearic acid. The excitation wavelength
was 360 nm and the emission fluorescence intensity was mon-
itored at 480 nm to diminish scattering from excitation light
and reabsorbance of the fluorescent light by haemoglobin at
415 nm.
Binding analysis
Assuming that the binding of each haemoglobin molecule
causes the same quenching of the fluorescence intensity, it was
possible to determine the binding constant, Ka, as described by
Lehrer & Fasman (25):
Ka
where β = - 
*L
(Eq. 1)
, and [Lf] = [L] - [C]; F0, FL, and F are
globin and total haemoglobin present, respectively, and [C] is
the concentration of binding sites in mol per litre. The value of
the binding constant was obtained by extrapolation of a plot
of 1/F-F0 vs 1/[L] to 1/[L] = 0 to obtain 1/FL-F0. The
binding constant, Ka, was calculated from the slope of a plot
of[Lf]vs /l- (26).
Results
The binding of haemoglobin to erythrocyte ghost
membranes was examined by fluorimetric titration.
The emission spectra of membrane-bound 12-(9-an-
throyl) stearic acid were typical for this fluorescent
probe (12), with the maximum at 440 nm. The addi-
tion of haemoglobin to 12-(9-anthroyl) stearic acid-
labelled erythrocyte membrane suspensions resulted
in a quenching of the fluorescence intensity but it did
not change the shape of the spectrum, or the position
of the maximum. This suggests that the decrease in
the fluorescence quantum yield was caused by energy
transfer from 12^(9^anthroyl) stearic acid to haemo-
globin, which has an absorbance maximum at 415
nm. The quenching experiments were performed with
erythrocyte ghosts from both non-diabetic and dia-
betic individuals in 8 independent experiments. Two
solutions of haemoglobin were used as described in
Materials and Methods, one considered to contain
non-glycated, the other glycated haemoglobin.
The plots of the data obtained according to Equation
1 are shown in figure 1. Each point of the plots
represents the mean value taken from 8 measure-
the fluorescence intensities of unliganded binding sites, fully
liganded binding sites, and of the experimental mixture, re-
spectively; [Lf] and [L] are the concentrations of free haemo-
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Fig. 1. Fluorimetric titration of human erythrocyte ghosts from
diabetic and non-diabetic individuals with glycated and
non-glycated haemoglobin
For further explanations see Materials and Methods,
section Binding analysis
Ο membranes from non-diabetic individuals -4- glycated
haemoglobin
ο membranes from non-diabetic individuals -f normal
haemoglobin
D membranes from diabetic individuals 4- glycated
haemoglobin
α membranes from diabetic individuals + normal hae-
moglobin .;
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Die PMN-Elastase ist einer der sen-
sitivsten Parameter zur Diagnose
einer Entzündung. Die bekannte
2 h-Version ermöglicht die Bestim-
mung aus Plasma, Stenalmark- und
Synovialflüssigkeit und weiterem
Untersuchungsmaterial. Ab Oktober
1988 steht der homogene Enzym-
immunoassay PMN-Elastase IMAC
zur Verfügung, er liefert aus dem
Plasma innerhalb von 10 Minuten,
bei manueller Methode innerhalb
von 20 Minuten, die Entscheidungs-
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ments. Straight lines were fitted by the method of the
least squares. From the slopes of these plots the bind-
ing constants, Ka, for each combination of ghosts and
haemoglobins were calculated. Results are given in
table 1. The double reciprocal plots of the percentage
of fluorescence quenched (β) versus free haemoglobin
concentration (Lf) are shown in figure 2. The fractions
of fluorescence quenched at infinity (l/Lr —»0) are
different for glyeated and non-glycated haemoglobin,
and they also depend on the type of erythrocyte
ghosts. The highest value for association is that of
non-glycated Hb with ghosts from diabetics (85%).
Results are summarized in table 2.
Discussion
Measurements of resonance energy transfer between
a fluorescent probe inserted into the lipid bilayer of
an erythrocyte membrane and the haem of membrane-
bound haemoglobin provided values for the binding
constants of red blood cell membranes from non-
diabetics or diabetics to normal or glyeated human
haemoglobin. The binding studies were done at low
concentrations of haemoglobin, low ionic strength,
and low pH. Such conditions are considered to cause
maximal binding of haemoglobin to the erythrocyte
membrane (27, 28), but are far from being physiolog-








Fig. 2. Double reciprocal plots of the fraction of fluorescence
intensity quenched versus free haemoglobin concentra-
tion.
For further explanations see Materials and Methods,
section Binding analysis
ο membranes from non-diabetic individuals + glyeated
haemoglobin
• membranes from non-diabetic individuals + normal
haemoglobin
α membranes from diabetic individuals + glyeated
haemoglobin
• membranes from diabetic individuals + normal hae-
moglobin
Tab. 1. Binding constants of glyeated and non-glycated hae-
moglobin to erythrocyte ghost membranes from dia-
betic and non-diabetic individuals




Ka x 108 [rnol/1]-1
Haemoglobin
0.91 ± 0.06 ρ < 0.001
ρ < 0.05






Results are expressed as mean ± SD, n = 8
Tab. 2. The fractions of fluorescence quenched at infinity
(Lr-* oo) by Hb and glyeated haemoglobin for eryth-





Control 0.82 ± 0.013 p < 0.001 0.70 ± 0.021
N.S. p < 0.05
0.85 ± 0.009 p < 0.01 0.79 ± 0.017
Results are expressed as mean ± SD, n = 8
membrane is in good agreement with the binding
constant obtained by Shaklai et al. (12) using the
same experimental conditions (Kd = 0.85 χ 108(mol/
I"1)). It was later suggested that at the concentrations
of Hb required for fluorescence studies (~ 10~7
rnol/1), oxyhaemoglobin is 97% dimeric, not tetra-
meric, and the new value for the binding constant was
0.53 χ 107 (mmol/l)-' (24). Results given in table 1
and 2 show that non-glycated haemoglobin exhibits
a higher affinity for membranes from diabetics as
compared to control erythrocyte ghosts. On the other
hand, the binding of glyeated haemoglobin to red
blood cell membranes from both normal and diabetic
individuals is significantly impaired. However, be-
cause glyeated haemoglobin is only a minor fraction
of total haemoglobin, even in diabetic subjects, the
increased binding of non-glycated haemoglobin to
erythrocyte membranes from diabetics seems to be
the predominant effect of haemoglobin binding in
diabetic individuals. Additionally, our experience with
the preparation of erythrocyte ghosts indicates that
membranes from diabetics usually need more inten-
sive washing to give haemoglobin-free white ghosts.
It has been shown that the band 3 protein is a hae-
moglobin-binding site in the erythrocyte membrane
(12—17). The amino-terminal 23-residue fragment of
band 3, with 14 of its residues being negatively
charged, is required for haemoglobin binding (18).
This finding provided additional evidence that bind-
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ing of haemoglobin to the membrane is electrostatic
in nature. It has been postulated that association
depends also on the size of the positive charge on
haemoglobin, since a direct relationship was observed
between the positive net charge of different haemo-
globin species and their affinities for erythrocyte mem-
branes (29). Furthermore, it has been shown that the
β chain of haemoglobin binds preferentially to the
erythrocyte membrane (30). Thus the decrease of
binding constant for glycated haemoglobin may be
due to the fact that glycation of the N-terminal amino
groups of the β chains of haemoglobin causes a de-
crease in the positive charge of the protein (31), thus
diminishing the electrostatic interactions between the
β chain of haemoglobin and the negatively charged
region of the band 3 protein. At this stage of the
experiments, it is difficult to offer a reason for the
higher affinity of membranes of diabetics both for
glycated and for non-glycated haemoglobin. One
could postulate that the altered net charge of mem-
brane proteins caused by increased glycation of mem-
branes from diabetics (10, 11) is responsible for this
effect. It was also estimated that approximately 50%
of band 3 protein may normally interact with hae-
moglobin and that in pathological cases with the
depletion of glycerate 2,3-bisphosphate, more hae-
moglobin can bind to band 3 since glycerate 2,3-
bisphosphate competes with band 3 for deoxyhae-
moglobin (17). Thus the lower glycerate 2,3-bisphos-
phate concentrations found in diabetes mellitus (33),
should result in an increased pool of haemoglobin
able to bind to the membrane. As a result there would
be less free band 3 protein available for binding other
cytosolic proteins, i. e. the glycolytic enzymes.
All these findings lead to the conclusion that under
physiological conditions one can expect alterations in
haemoglobin binding to the erythrocyte membrane in
diabetes, although the biological significance of this
association remains unclear. It was suggested (15) that
haemoglobin molecules that interact with the mem-
brane may act as perturbants to the dynamic structure
of the cell membranes, affecting their structural and
functional properties. This could have pathological
consequences as was found for sickle red blood cells,
where enhanced binding of haemoglobin was reported
(32). However, further studies of haemoglobin-eryth-
rocyte membrane interactions in diabetes under phys-
iological conditions are needed to establish the exist-
ence of differences in these interactions under these
conditions, and their possible pathological role.
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